85952-32-5

Usage

Application

2-Trifluoromethylbenzylsulfonyl chloride is a useful research chemical.

InChI:InChI=1/C8H6ClF3O2S/c9-15(13,14)5-6-3-1-2-4-7(6)8(10,11)12/h1-4H,5H2

Upstream product

• 862896-97-7 (2-trifluoromethylphenyl)methanesulfonic acid 

Downstream Products

• 1123754-33-5 (R)-1-(1H-indol-3-yl)-2-(2-trifluoromethylphenylmethanesulfonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1335290-41-9 1-(2,2-difluoroethyl)-2,2-dioxo-3-(2-trifluoromethyl-phenyl)-1,2-dihydro-2-thia-1,5-diazanaphthalen-4-ol 
• 1335292-51-7 methyl 3-[(2,2-difluoroethyl)(2-trifluoromethylphenylmethanesulfonyl)amino]-pyridine-2-carboxylate 
• 1123754-39-1 (S)-1-(1H-indol-3-yl)-2-(2-trifluoromethyl-phenylmethanesulfonyl)-1,2,3,4-tetrahydro-isoquinoline 
• 112941-35-2 (2-trifluoromethylphenyl)-methanesulfonamide 
• 862896-97-7 (2-trifluoromethylphenyl)methanesulfonic acid 

Relevant academic research and scientific papers

Alkyne Linchpin Strategy for Drug:Pharmacophore Conjugation: Experimental and Computational Realization of a Meta-Selective Inverse Sonogashira Coupling

The late-stage functionalization (LSF) of pharmaceutical and agrochemical compounds by the site-selective activation of C-H bonds provides access to diverse structural analogs and expands synthetically-accessible chemical space. We report a C-H functionalization LSF strategy that hinges on the use of an alkyne linchpin to assemble conjugates of sp2-rich marketed pharmaceuticals and agrochemicals with sp3-rich 3D fragments and natural products. This is accomplished through a template-assisted inverse Sonogashira reaction that displays high levels of selectivity for the meta position. This protocol is also amenable to distal structural modifications of α-amino acids. The transformation of alkyne functionality to other functional groups further highlights the applicative potential. Computational and experimental mechanistic studies shed light on the detailed mechanism. Turnover-limiting 1,2-migratory insertion of the bromoalkyne coupling partner occurs after relatively fast C-H activation. While this insertion occurs unselectively, regioconvergence results from one of the adducts undergoing a 1,2-trialkylsilyl migration to form the alkynylated product. A heterobimetallic Pd-Ag transition structure is essential for product formation in the β-bromide elimination step.

PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION

The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}p

Process for the synthesis of sulfonyl halides and sulfonamides from sulfonic acid salts

The present invention provides synthetic processes for the preparation of sulfonyl halides of Formula Ar—(R)z—O2—X and sulfonamides of Formula Ar—(R)2—SO2—NR4R5, where the constituent varia

INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides

The present invention provides processes for the preparation of arylalkylsulfonyl halides and heteroarylalkylsufonyl halides of Formula I: Ar—R—SO2—X, that are useful as intermediates in the preparation of pharmaceuticals.